Skip to main content

Table 1 Baseline characteristics

From: Soluble Klotho is not independently associated with cardiovascular disease in a population of dialysis patients

  Total cohort Klotho <460 pg/mL Klotho >460 pg/mL
  n = 127 n = 63 n = 64
Age, years 67 ± 7 67 ± 7 67 ± 8
Gender, female 30 (24%) 10 (16%) 20 (31%)*
Pulse pressure, mmHg 59 ± 24 59 ± 24 59 ± 16
Hypertension 104 (82%) 53 (87%) 51 (80%)
Diabetes 43 (34%) 24 (40%) 19 (30%)
Dialysis Modality, PD 42 (33%) 8 (13%) 34 (53%)***
Dialysis vintage, years 2.3 ± 2 2.6 ± 2.7 2.0 ± 2.2
RRF, (ml/min/1.73 m2) 1.8 ± 1.6 1.7 ± 1.8 2.0 ± 1.4
Anuria 30 (24%) 20 (33%) 10 (16%)*
Phosphate (mmol/L) 1.5 ± 0.4 1.6 ± 0.4 1.5 ± 0.4
Calcium (mmol/L) 2.4 ± 0.2 2.4 ± 0.2 2.4 ± 0.2
FGF-23 (RefU/mL) 7247 ± 16815 8723 ± 21627 5794 ± 10044
25(OH)D (nmol/L) 87 ± 57 102 ± 65 71 ± 42**
PTH (pmol/L) 35 ± 34 42 ± 41 28 ± 22*
Creatinine (umol/L) 659 ± 202 642 ± 211 676 ± 195
CRP (mg/L) 14.3 ± 30.7 20.1 ± 41.7 8.9 ± 12.22*
β -blocker 71 (56%) 37 (60%) 34 (54%)
ACEi 32 (25%) 19 (31%) 13 (21%)
ARB 37 (29%) 13 (21%) 24 (38%)*
Statin 79 (62%) 43 (69%) 36 (57%)
NCPB 107 (84%) 54 (87%) 53 (84%)
CCPB 50 (39%) 25 (40%) 25 (40%)
Cinacalcet 15 (12%) 7 (12%) 8 (13%)
  1. PD; Peritoneal dialysis, RRF; Residual Renal Function, FGF-23; Fibroblast Growth Factor 23. PTH; Parathyroid hormone, ACEí; Angiotensin Converting Enzyme inhibitor, ARB; Angiotensin receptor blocker, NCPB; Non calcium containing phosphate binder, CCPB; Calcium containing phosphate binder. *;p < 0.05, **;p < 0.01; ***;p < 0.001.